What’s next for pay-for-delay after Supreme Court victory?
When the Supreme Court recently ruled that pay-for-delay agreements between brand and generic drug companies are subject to antitrust scrutiny, officials at the Federal Trade Commission had every right to feel...
Subscription required to view this article.This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: